San Diego-based ResMed and Verily, a subsidiary of Google parent company Alphabet, have formed a new venture to develop software for identifying, diagnosing and treating sleep apnea and other breathing disorders.
The partnership joins ResMed’s sleep apnea experience – encompassing devices and digital initiatives -- with Verily’s data analytics technologies. Along with developing software, they’ll study the health and financial impacts of undiagnosed sleep apnea.
The malady affects an estimated 54 million Americans, and past research suggests 80 percent of the people with obstructive sleep apnea are undiagnosed and untreated. ResMed has sought to bolster awareness, stating the company’s greatest competitor is ignorance.
This venture will operate separately from ResMed and Verily.